Aridis pharmaceuticals announces a pan-coronavirus monoclonal antibody cocktail that retains effectiveness against the omicron variant, other covid-19 variants, sars, mers, and the common cold human coronaviruses

Los gatos, calif., dec. 21, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its fully human monoclonal antibody (mab) cocktail ar-701 is broadly reactive against the omicron and other covid-19 (sars-cov-2) variants, sars (severe acute respiratory syndrome), mers (middle east respiratory syndrome coronavirus), and seasonal ('common cold') human coronaviruses.
ARDS Ratings Summary
ARDS Quant Ranking